| Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis D Adams, A Gonzalez-Duarte, WD O’Riordan, CC Yang, M Ueda, ... New england journal of medicine 379 (1), 11-21, 2018 | 2403 | 2018 |
| Inotersen treatment for patients with hereditary transthyretin amyloidosis MD Benson, M Waddington-Cruz, JL Berk, M Polydefkis, PJ Dyck, ... New England Journal of Medicine 379 (1), 22-31, 2018 | 1227 | 2018 |
| Safety and efficacy of RNAi therapy for transthyretin amyloidosis T Coelho, D Adams, A Silva, P Lozeron, PN Hawkins, T Mant, J Perez, ... New England Journal of Medicine 369 (9), 819-829, 2013 | 1055 | 2013 |
| Translocator protein (18 kDa)(TSPO) as a therapeutic target for neurological and psychiatric disorders R Rupprecht, V Papadopoulos, G Rammes, TC Baghai, J Fan, N Akula, ... Nature reviews Drug discovery 9 (12), 971-988, 2010 | 988 | 2010 |
| Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 … VC Marconi, AV Ramanan, S de Bono, CE Kartman, V Krishnan, R Liao, ... The lancet Respiratory medicine 9 (12), 1407-1418, 2021 | 671 | 2021 |
| Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised … P Nash, B Kirkham, M Okada, P Rahman, B Combe, GR Burmester, ... The Lancet 389 (10086), 2317-2327, 2017 | 443 | 2017 |
| Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis: analysis of the APOLLO study SD Solomon, D Adams, A Kristen, M Grogan, A González-Duarte, ... Circulation 139 (4), 431-443, 2019 | 418 | 2019 |
| Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological … D van der Heijde, JCC Wei, M Dougados, P Mease, A Deodhar, ... The Lancet 392 (10163), 2441-2451, 2018 | 354 | 2018 |
| Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy C Bouchard, C Lacroix, V Plante, D Adams, F Chedru, JM Guglielmi, ... Neurology 52 (3), 498-498, 1999 | 350 | 1999 |
| Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease D Adams, H Koike, M Slama, T Coelho Nature Reviews Neurology 15 (7), 387-404, 2019 | 330 | 2019 |
| Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study OB Suhr, T Coelho, J Buades, J Pouget, I Conceicao, J Berk, H Schmidt, ... Orphanet journal of rare diseases 10, 1-9, 2015 | 326 | 2015 |
| The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation D Adams, D Samuel, C Goulon-Goeau, M Nakazato, PMP Costa, C Feray, ... Brain 123 (7), 1495-1504, 2000 | 287 | 2000 |
| Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP) V Planté-Bordeneuve, A Ferreira, T Lalu, C Zaros, C Lacroix, D Adams, ... Neurology 69 (7), 693-698, 2007 | 267 | 2007 |
| First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy D Adams, OB Suhr, E Hund, L Obici, I Tournev, JM Campistol, MS Slama, ... Current opinion in neurology 29, S14-S26, 2016 | 257 | 2016 |
| Evolving landscape in the management of transthyretin amyloidosis PN Hawkins, Y Ando, A Dispenzeri, A Gonzalez-Duarte, D Adams, ... Annals of medicine 47 (8), 625-638, 2015 | 253 | 2015 |
| A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression EB Brown, SL McElroy, PE Keck Jr, A Deldar, DH Adams, M Tohen, ... Journal of Clinical Psychiatry 67 (7), 1025-1033, 2006 | 251 | 2006 |
| Multifocal motor neuropathy with conduction block: a study of 24 patients. P Bouche, A Moulonguet, AB Younes-Chennoufi, D Adams, N Baumann, ... Journal of Neurology, Neurosurgery & Psychiatry 59 (1), 38-44, 1995 | 226 | 1995 |
| Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management … Y Parman, D Adams, L Obici, L Galán, V Guergueltcheva, OB Suhr, ... Current opinion in neurology 29, S3-S13, 2016 | 218 | 2016 |
| Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial A Deodhar, D van der Heijde, LS Gensler, TH Kim, WP Maksymowych, ... The Lancet 395 (10217), 53-64, 2020 | 215 | 2020 |
| Hereditary Systemic Amyloidosis Due to Asp76Asn Variant β2-Microglobulin S Valleix, JD Gillmore, F Bridoux, PP Mangione, A Dogan, B Nedelec, ... New England Journal of Medicine 366 (24), 2276-2283, 2012 | 215 | 2012 |
